{"id":3461,"count":12,"description":"Tulbur\u0103rile legate de consumul de substan\u021be sunt <strong>afec\u021biuni medicale cronice, tratabile<\/strong> \u2014 nu e\u0219ecuri ale voin\u021bei. Farmacoterapia este o component\u0103 a tratamentului, al\u0103turi de consiliere, sprijinul colegial (AA, SMART Recovery, NA), evaluarea clinic\u0103 periodic\u0103 \u0219i gestionarea afec\u021biunilor de s\u0103n\u0103tate mintal\u0103 coexistente. Medicamentele de mai jos abordeaz\u0103 trei dependen\u021be distincte prin mecanisme complementare; alegerea optim\u0103 pentru un pacient depinde de substan\u021ba tratat\u0103, obiectiv (abstinen\u021b\u0103 vs reducere), afec\u021biuni comorbide, func\u021bia organelor, motiva\u021bie \u0219i disponibilitatea suportului comportamental.\n\n<strong>\u00cencetarea fumatului \u2014 agonist par\u021bial al receptorilor nicotinici.<\/strong> <strong>Champix<\/strong> (vareniclina 1 mg) este unul dintre cele mai eficiente agen\u021bi singulari pentru dependen\u021ba de tutun, produc\u00e2nd rate de abstinen\u021b\u0103 la 1 an de aproximativ dou\u0103 p\u00e2n\u0103 la trei ori mai mari dec\u00e2t placebo. Ca agonist par\u021bial la receptorul nicotinic-acetilcolin\u0103 \u03b14\u03b22, reduce poftele \u0219i blocheaz\u0103 efectul gratificant al oric\u0103rei \u021big\u0103ri fumate \u00een timpul tratamentului. Protocolul de 12 s\u0103pt\u0103m\u00e2ni titreaz\u0103 de la 0,5 mg o dat\u0103 pe zi la 1 mg de dou\u0103 ori pe zi, cu o dat\u0103 de \u00eencetare stabilit\u0103 la 8\u201314 zile de la \u00eenceperea terapiei; 12 s\u0103pt\u0103m\u00e2ni suplimentare de \u00eentre\u021binere aproape dubleaz\u0103 abstinen\u021ba la 1 an. Avertizarea FDA din 2009 a fost eliminat\u0103 \u00een 2016 dup\u0103 ce studiul EAGLES nu a g\u0103sit un exces semnificativ de evenimente neuropsihiatrice. Ajustarea dozei este necesar\u0103 la eGFR &lt; 30.\n\n<strong>Tulburarea de consum de alcool \u2014 inhibarea aldehid-dehidrogenazei (descurajare).<\/strong> <strong>Cronotol<\/strong> 500 mg, <strong>Esperal<\/strong> 250 mg, <strong>Dizone<\/strong> 250 mg, \u0219i <strong>Firam<\/strong> 250 mg sunt toate <strong>disulfiram<\/strong>: cea mai veche terapie farmacologic\u0103 autorizat\u0103 pentru tulburarea de consum de alcool (AUD), utilizat\u0103 \u00een clinic\u0103 din 1949. Prin inhibarea ireversibil\u0103 a aldehidei dehidrogenaze, disulfiramul determin\u0103 acumularea de acetaldehid\u0103 atunci c\u00e2nd este consumat alcool \u2014 reac\u021bia disulfiram\u2013etanol (ro\u0219ea\u021b\u0103, grea\u021b\u0103, palpita\u021bii, hipotensiune). Acesta este un <strong>deterrent mai degrab\u0103 dec\u00e2t un medicament care reduce pofta<\/strong> \u0219i func\u021bioneaz\u0103 cel mai bine la pacien\u021bii motiva\u021bi cu supraveghere structurat\u0103. Doza de 500 mg (Cronotol) este utilizat\u0103 \u00een faza de \u00eenc\u0103rcare; formul\u0103rile de 250 mg (Esperal, Dizone, Firam) reprezint\u0103 doza standard de \u00eentre\u021binere. <strong>Pacien\u021bii trebuie s\u0103 fie abstinen\u021bi de la alcool timp de cel pu\u021bin 12 ore \u00eenainte de prima doz\u0103<\/strong>, trebuie s\u0103 evite sursele ascunse de etanol (ap\u0103 de gur\u0103, sirop de tuse, o\u021bet, ap\u0103 after-shave, dezinfectant de m\u00e2ini, alimente fermentate) \u0219i necesit\u0103 monitorizarea func\u021biei hepatice (LFT) la baz\u0103 + la 2 s\u0103pt\u0103m\u00e2ni + lunar \u00een primele 3 luni din cauza toxicit\u0103\u021bii hepatice idiosincratice rare. Nu se administreaz\u0103 concomitent cu metronidazol, tinidazol sau izoniazid\u0103.\n\n<strong>Tulburare de consum de alcool sau opioide \u2014 antagonism al receptorilor de opioide (reducerea poftei).<\/strong> <strong>Nalsign<\/strong>, <strong>Nalcon<\/strong>, <strong>Nodict<\/strong>, \u0219i <strong>Naltima<\/strong> sunt <strong>naltrexon\u0103 50 mg<\/strong>, un antagonist pe termen lung al receptorilor \u03bc-opioizi. \u00cen tulburarea de consum de alcool, atenueaz\u0103 recompensa consumului de alcool (studiu COMBINE, 2006); \u00een tulburarea de consum de opioide, blocheaz\u0103 efectul oric\u0103rui opioid consumat. Spre deosebire de disulfiram, naltrexona nu produce nicio reac\u021bie aversiv\u0103 \u2014 o sc\u0103pare este ne\u00eensemnat\u0103, ceea ce este util terapeutic. <strong>Pacien\u021bii trebuie s\u0103 fie abstinen\u021bi de la opioide timp de 7\u201310 zile<\/strong> (14 zile pentru metadon\u0103) \u00eenainte de a \u00eencepe tratamentul pentru tulburarea de consum de opioide (OUD), altfel naltrexona poate precipita sevraj sever; majoritatea prescriitorilor efectueaz\u0103 un test de provocare cu naloxon\u0103 \u00eenainte de prima doz\u0103. Considera\u021bie opera\u021bional\u0103 major\u0103: <strong>analgezia opioid\u0103 este \u00een mare parte blocat\u0103 \u00een timpul administr\u0103rii naltrexonei<\/strong> \u2014 echipele chirurgicale, dentare \u0219i de urgen\u021b\u0103 trebuie informate, iar un card de portofel trebuie purtat.\n\n<strong>Tratamentul de \u00eentre\u021binere pentru tulburarea de consum de alcool \u2014 modulare NMDA\/glutamat.<\/strong> <strong>Acamptas 333 mg<\/strong> \u0219i <strong>Acamprol 333 mg<\/strong> sunt <strong>acamprosat de calciu<\/strong>, a doua terapie farmacologic\u0103 oral\u0103 de prim\u0103 linie pentru tulburarea de consum de alcool (AUD) al\u0103turi de naltrexon\u0103. Dup\u0103 consumul cronic \u0219i excesiv de alcool, creierul supraregleaz\u0103 receptorii NMDA de glutamat \u0219i subregleaz\u0103 receptorii GABA-A ca adaptare; la \u00eencetare, aceasta las\u0103 o hiperactivitate relativ\u0103 a glutamatului, produc\u00e2nd sindromul post-\u00eencetare prelungit (insomnie, anxietate, iritabilitate, disforie) care determin\u0103 rec\u0103derea tardiv\u0103. Acamprosatul moduleaz\u0103 func\u021bia receptorilor NMDA \u0219i ajut\u0103 creierul s\u0103 se reechilibreze. Doza standard este de dou\u0103 comprimate de 333 mg de trei ori pe zi (1.998 mg\/zi) cu alimente; doza se \u00eenjum\u0103t\u0103\u021be\u0219te la eGFR 30\u201350 \u0219i acamprosatul este contraindicat sub eGFR 30. Profilul de interac\u021biuni este excep\u021bional de curat (f\u0103r\u0103 metabolism hepatic, f\u0103r\u0103 activitate CYP), f\u0103c\u00e2ndu-l agentul preferat pentru AUD la pacien\u021bii cu afec\u021biuni hepatice stabilite.\n\n<strong>Adjuvant off-label \u2014 anticonvulsivant multi-mecanism.<\/strong> <strong>Topamac<\/strong> (topiramate 25 \/ 50 mg) is licensed for epilepsy and migraine prophylaxis but has substantial evidence (Johnson 2007) for off-label use in alcohol use disorder, particularly in patients who have not responded to naltrexone or acamprosate or who have comorbid migraine. Multi-mechanistic action (sodium-channel blockade, GABA-A potentiation, glutamate AMPA antagonism, carbonic anhydrase inhibition) is thought to dampen reward circuitry. Slow titration (25 mg per week over 8 weeks to a 100&ndash;300 mg\/day target) is essential because cognitive side effects (\"topa-dopa\": word-finding difficulty, mental slowing) are dose-limiting. Specific safety considerations: 2&ndash;3-fold increase in oral cleft malformation in first-trimester pregnancy (effective contraception is mandatory), nephrolithiasis (~1.5%, mitigated by aggressive hydration), rare acute angle-closure glaucoma (any eye pain or visual change in the first month is an emergency), and metabolic acidosis. Renal-dose adjusted.\n\n<strong>Cum s\u0103 alegi:<\/strong> pentru dependen\u021ba de tutun, vareniclina este monoterapia de prim\u0103 linie; pentru tulburarea de consum de alcool, ghidurile actuale (NICE, APA, ASAM) plaseaz\u0103 <strong>naltrexona \u0219i acamprosatul ca tratamente de prim\u0103 linie<\/strong> \u2014 alege\u021bi naltrexon\u0103 atunci c\u00e2nd pofta \u0219i recompensa sunt principalii factori de rec\u0103dere, alege\u021bi acamprosat atunci c\u00e2nd sindromul post-\u00eencheiere al hiperactivit\u0103\u021bii glutamatice prelungite (somn, anxietate, disforie) este dominant, sau \u00een cazul afec\u021biunilor hepatice stabilite. Disulfiramul este o op\u021biune puternic\u0103 de linia a doua pentru pacien\u021bii foarte motiva\u021bi cu supraveghere zilnic\u0103 structurat\u0103. Topiramatul este o op\u021biune rezonabil\u0103 off-label dup\u0103 e\u0219ecul terapiei de prim\u0103 linie sau \u00een cazul migrenei comorbide. Pentru tulburarea de consum de opioide, naltrexona este op\u021biunea necontrolat\u0103; terapia cu agonisti de opioide (metadon\u0103, buprenorfin\u0103) este alternativa \u0219i adesea preferat\u0103 acolo unde aderen\u021ba este incert\u0103. <strong>Toate tratamentele farmacologice func\u021bioneaz\u0103 substan\u021bial mai bine atunci c\u00e2nd sunt asociate cu sprijin comportamental structurat<\/strong> &mdash; the medication does not treat the disorder alone.\n\nAll MedsBase stock is sourced from <strong>produc\u0103tori certifica\u021bi WHO-GMP<\/strong>, livrate \u00een ambalaje discrete \u0219i acoperite de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu ajunge, \u00eel relivr\u0103m gratuit.","link":"https:\/\/medsbase.com\/ro\/alcohol-and-drug-treatment\/","name":"Tratamentul alcoolismului \u0219i dependen\u021bei de droguri","slug":"alcohol-and-drug-treatment","taxonomy":"product_cat","parent":3342,"meta":[],"menu_order":0,"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat\/3461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"up":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat\/3342"}],"wp:post_type":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product?product_cat=3461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}